Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

In this true-story musical comedy adaption of the infamous Allied Forces tactic during World War II, no one has any fun.

Loyal Jake Shane followers, a.k.a. "Pussies," are familiar with the long running gag that he is on Ozempic - and now he's ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.

Like Aly, Abdul-Rahman also stresses that GLP-1 medications are a treatment for diabetes and obesity, and as such, they do ...